摘要
目的:探讨HLA半相合的活化造血干细胞(haplo-HSCs)对晚期癌症患者的抗肿瘤及免疫调节作用。方法:42例晚期癌症患者分别通过体外对肿瘤细胞的杀伤活性检测、临床影像学检查以及外周血淋巴细胞亚群、细胞因子变化情况来评估抗肿瘤及免疫调节作用。结果:活化后haplo-HSCs在体外的非特异性杀瘤活性显著提高(P<0.01),而临床有效率(CR+PR)为16.67。治疗后患者的CD3+、CD4+、CD4+/CD8+、CD3-CD16+56+(NK)均明显升高(P<0.05),而CD8+、CD4+CD25+(Tregs)明显降低(P<0.05);TNF-α、IFN-γ等Th1类细胞因子明显升高(P<0.01),而TGF-β明显下降(P<0.05)。结论:HLA半相合的活化造血干细胞(haplo-HSCs)治疗后,宿主细胞免疫功能明显增强,同时机体产生特异性的抗肿瘤免疫作用。
Objective： To evaluate the anti-tumor and immunoregulatory activities of activated HLA haploidentical hematopoietic stem cells on the advanced carcinoma patients.Methods： Forty-two advanced carcinoma patients were enrolled in this treatment. The anti-tumor and immunoregulatory activities were evaluated by Lyric activity against tumor cells, imaging examination, lymphocytes subset and cytokine changes respectively. Results：In vitro,the activity of kill tumor cells was increased significantly after activation. The total effective rate（ CR ＋ PR）was 16.67%. The levels of CD3^＋ , CD4 ^＋, CD4^ ＋/CD8^＋ , CD3^- CD16^＋ 56 ^＋ （NK） were increased significantly after treatment （ P 〈 0. 05 ）, but CD8^＋ , CD4 ^＋ CD25^＋ （Tregs）were decreased significantly （ P 〈 0.05） ; Thl cytokine （TNF-α, IFN-γ） obviously increased（ P 〈 0.01 ）, in contrast TGF-β decreased（ P 〈 0.05）. Conclusion： The activated HIA haploidentical hematopoietic stem cells can enhance the cellular immune function and specific anti-tumor activation for the advanced carcinoma patients.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2009年第7期626-629,共4页
Chinese Journal of Immunology
基金
国家十五科技攻关引导项目(No:2005BA740C)资助
关键词
恶性肿瘤
单倍相合
异基因造血干细胞
免疫治疗
Malignant carcinoma
Haploidentical
AUogeneic hematopoietic stem cells
Immunotherapy
